May 1, 2007 Treatment Action Group (TAG) supports the approval of maraviroc for treatment of HIV infection in patients with prior antiretroviral experience. Maraviroc is an orally-available small molecule that binds to and alters the shape of CCR5, a cell…
February 8, 2007 About the Palm Project Interviews TAG has conducted a series of interviews with leading scientists about the underlying pathogenesis of AIDS to gain insights into emerging lines of research and observations about the current research funding environment…
February 8, 2007 About the Palm Project Interviews TAG has conducted a series of interviews with leading scientists about the underlying pathogenesis of AIDS to gain insights into emerging lines of research and observations about the current research funding environment…
February 8, 2007 About the Palm Project Interviews TAG has conducted a series of interviews with leading scientists about the underlying pathogenesis of AIDS to gain insights into emerging lines of research and observations about the current research funding environment…
What’s in the Pipeline: New HIV Drugs, Vaccines, Microbicides, HCV and TB Therapies in Clinical Trials By Rob Camp, Richard Jefferys, Tracy Swan & Javid Syed Edited by Bob Huff August 2006 From the Forword: Twenty-five years into the global…
By Rob Camp May 25, 2006 Darunavir (DRV) is a ritonavir(r)-boosted protease inhibitor that has been studied for use in heavily treatment-experienced patients. In the future, DRV/r will be evaluated for use in less-experienced, treatment-naïve and pediatric populations. The current…
Published 2006 This publication is cosponsored by the Open Society Institute, a private operating and grantmaking foundation whose aim is to shape public policy in order to promote democratic governance, human rights, and economic, legal, and social reform, and the…
by Mark Harrington Remarks at Boehringer Ingelheim Symposium “HIV: From Yesterday to Tomorrow / HIV: da ieri in poi” Sheraton Golf Parco de’Medici 6 April 2006 Rome * [Note: This is a revised and expanded version of remarks I gave…
The Treatment Action Group (TAG) today expressed disappointment that SMART, a large, international study comparing CD4-guided, intermittent antiretroviral therapy to continuous treatment, has had to be stopped due to a significantly higher incidence of clinical events in the intermittent treatment arm.